Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications

Marc A. Rodger, Marc Carrier, Gr'egoire Le Gal, Ida Martinelli, Annalisa Perna, Evelyne Rey, J. I P De Vries, Jean Christophe Gris

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

A 35-year-oldwomanwith recurrent severe placenta-mediated pregnancy complications in her 2 pregnancies asks: Will lowmolecular- weight heparin help prevent recurrent placenta-mediated pregnancy complications in my next pregnancy? We performed a meta-analysis of randomized controlled trials (RCTs) comparing low-molecular-weight heparin (LMWH) vs no LMWH for the prevention of recurrent placenta-mediated pregnancy complications. We identified six RCTs that included a total of 848 pregnant women with prior placenta-mediated pregnancy complications. The primary outcome was a composite of pre-eclampsia (PE), birth of a small-for-gestational-age (SGA) newborn (20 weeks. Overall, 67 (18.7%) of 358 of women being given prophylactic LMWH had recurrent severe placenta-mediated pregnancy complications compared with 127 (42.9%) of 296 women with no LMWH (relative risk reduction, 0.52; 95% CI, 0.32 to 0.86; P 5 .01; I2, 69%, indicating moderate heterogeneity). We identified similar relative risk reductions with LMWH for individual outcomes, including any PE, severe PE, SGA

Original languageEnglish
Pages (from-to)822-828
Number of pages7
JournalBlood
Volume123
Issue number6
DOIs
Publication statusPublished - Feb 6 2014

Fingerprint

Pregnancy Complications
Low Molecular Weight Heparin
Placenta
Meta-Analysis
Pre-Eclampsia
Risk Reduction Behavior
Gestational Age
Randomized Controlled Trials
Pregnancy
Heparin
Pregnant Women
Parturition
Newborn Infant
Weights and Measures
Composite materials

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. / Rodger, Marc A.; Carrier, Marc; Le Gal, Gr'egoire; Martinelli, Ida; Perna, Annalisa; Rey, Evelyne; De Vries, J. I P; Gris, Jean Christophe.

In: Blood, Vol. 123, No. 6, 06.02.2014, p. 822-828.

Research output: Contribution to journalArticle

Rodger, Marc A. ; Carrier, Marc ; Le Gal, Gr'egoire ; Martinelli, Ida ; Perna, Annalisa ; Rey, Evelyne ; De Vries, J. I P ; Gris, Jean Christophe. / Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. In: Blood. 2014 ; Vol. 123, No. 6. pp. 822-828.
@article{d0e5d349c1694aee834fe8c58a44d301,
title = "Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications",
abstract = "A 35-year-oldwomanwith recurrent severe placenta-mediated pregnancy complications in her 2 pregnancies asks: Will lowmolecular- weight heparin help prevent recurrent placenta-mediated pregnancy complications in my next pregnancy? We performed a meta-analysis of randomized controlled trials (RCTs) comparing low-molecular-weight heparin (LMWH) vs no LMWH for the prevention of recurrent placenta-mediated pregnancy complications. We identified six RCTs that included a total of 848 pregnant women with prior placenta-mediated pregnancy complications. The primary outcome was a composite of pre-eclampsia (PE), birth of a small-for-gestational-age (SGA) newborn (20 weeks. Overall, 67 (18.7{\%}) of 358 of women being given prophylactic LMWH had recurrent severe placenta-mediated pregnancy complications compared with 127 (42.9{\%}) of 296 women with no LMWH (relative risk reduction, 0.52; 95{\%} CI, 0.32 to 0.86; P 5 .01; I2, 69{\%}, indicating moderate heterogeneity). We identified similar relative risk reductions with LMWH for individual outcomes, including any PE, severe PE, SGA",
author = "Rodger, {Marc A.} and Marc Carrier and {Le Gal}, Gr'egoire and Ida Martinelli and Annalisa Perna and Evelyne Rey and {De Vries}, {J. I P} and Gris, {Jean Christophe}",
year = "2014",
month = "2",
day = "6",
doi = "10.1182/blood-2013-01-478958",
language = "English",
volume = "123",
pages = "822--828",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications

AU - Rodger, Marc A.

AU - Carrier, Marc

AU - Le Gal, Gr'egoire

AU - Martinelli, Ida

AU - Perna, Annalisa

AU - Rey, Evelyne

AU - De Vries, J. I P

AU - Gris, Jean Christophe

PY - 2014/2/6

Y1 - 2014/2/6

N2 - A 35-year-oldwomanwith recurrent severe placenta-mediated pregnancy complications in her 2 pregnancies asks: Will lowmolecular- weight heparin help prevent recurrent placenta-mediated pregnancy complications in my next pregnancy? We performed a meta-analysis of randomized controlled trials (RCTs) comparing low-molecular-weight heparin (LMWH) vs no LMWH for the prevention of recurrent placenta-mediated pregnancy complications. We identified six RCTs that included a total of 848 pregnant women with prior placenta-mediated pregnancy complications. The primary outcome was a composite of pre-eclampsia (PE), birth of a small-for-gestational-age (SGA) newborn (20 weeks. Overall, 67 (18.7%) of 358 of women being given prophylactic LMWH had recurrent severe placenta-mediated pregnancy complications compared with 127 (42.9%) of 296 women with no LMWH (relative risk reduction, 0.52; 95% CI, 0.32 to 0.86; P 5 .01; I2, 69%, indicating moderate heterogeneity). We identified similar relative risk reductions with LMWH for individual outcomes, including any PE, severe PE, SGA

AB - A 35-year-oldwomanwith recurrent severe placenta-mediated pregnancy complications in her 2 pregnancies asks: Will lowmolecular- weight heparin help prevent recurrent placenta-mediated pregnancy complications in my next pregnancy? We performed a meta-analysis of randomized controlled trials (RCTs) comparing low-molecular-weight heparin (LMWH) vs no LMWH for the prevention of recurrent placenta-mediated pregnancy complications. We identified six RCTs that included a total of 848 pregnant women with prior placenta-mediated pregnancy complications. The primary outcome was a composite of pre-eclampsia (PE), birth of a small-for-gestational-age (SGA) newborn (20 weeks. Overall, 67 (18.7%) of 358 of women being given prophylactic LMWH had recurrent severe placenta-mediated pregnancy complications compared with 127 (42.9%) of 296 women with no LMWH (relative risk reduction, 0.52; 95% CI, 0.32 to 0.86; P 5 .01; I2, 69%, indicating moderate heterogeneity). We identified similar relative risk reductions with LMWH for individual outcomes, including any PE, severe PE, SGA

UR - http://www.scopus.com/inward/record.url?scp=84894025152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894025152&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-01-478958

DO - 10.1182/blood-2013-01-478958

M3 - Article

C2 - 24357725

AN - SCOPUS:84894025152

VL - 123

SP - 822

EP - 828

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -